How should a febrile infant be evaluated and managed?

Evaluation and Management of Febrile Infants

Well-appearing febrile infants aged 8-60 days should be risk-stratified by age and inflammatory markers, with management ranging from outpatient oral antibiotics to full sepsis workup with hospitalization, based on the 2021 AAP guidelines 1.

Age-Based Risk Stratification

The evaluation fundamentally depends on the infant's age, dividing management into three distinct groups 1, 2:

8-21 Days Old: Highest Risk

• Full sepsis workup required: blood culture, urinalysis with culture, and lumbar puncture
• Empirical antibiotics mandatory: Ampicillin IV/IM (150 mg/kg/day divided q8h) PLUS either ceftazidime IV/IM (150 mg/kg/day divided q8h) OR gentamicin IV/IM (4 mg/kg q24h)
• Hospitalization required for observation and IV antibiotics
• If bacterial meningitis confirmed: increase ampicillin to 300 mg/kg/day divided q6h with ceftazidime 1

22-28 Days Old: Intermediate Risk

• Inflammatory markers (IM) guide management: procalcitonin, C-reactive protein, absolute neutrophil count, and temperature >38.4°C 3
• If IM normal AND urinalysis normal: lumbar puncture may be deferred using shared decision-making with parents 1
• If any IM abnormal: full sepsis workup including LP required
• Empirical therapy: Ceftriaxone IV/IM (50 mg/kg q24h) 1
• If meningitis: Ampicillin IV (300 mg/kg/day divided q6h) plus ceftazidime 1

29-60 Days Old: Lower Risk with Conditional Management

• Low-risk criteria allow selective testing: If inflammatory markers normal AND urinalysis normal, LP may be avoided 1, 3
• UTI-only pathway possible: If only urinalysis abnormal with normal inflammatory markers, can treat as isolated UTI with oral antibiotics (cephalexin 50-100 mg/kg/day in 4 doses OR cefixime 8 mg/kg/day once daily) 1
• Outpatient management feasible for low-risk infants with reliable follow-up and shared decision-making 4
• If IM abnormal: parenteral ceftriaxone (50 mg/kg q24h) with hospitalization 1
• If meningitis: Ceftriaxone IV (100 mg/kg/day) or ceftazidime (150 mg/kg/day divided q8h) plus vancomycin IV (60 mg/kg/day divided q8h) 1

Critical Exclusion Criteria

These guidelines apply ONLY to 1, 5:

• Well-appearing infants (ill-appearing infants require full workup regardless of age)
• Term infants (≥37 weeks gestation)
• Temperature ≥38.0°C (100.4°F) rectally
• Exclude: prematurity, focal bacterial infections (except acute otitis media), suspected herpes simplex virus (vesicles present), clinical bronchiolitis

Key Diagnostic Testing

Inflammatory markers are the game-changer in the 2021 guidelines 3:

• Procalcitonin (preferred biomarker)
• C-reactive protein
• Absolute neutrophil count
• Temperature >38.4°C itself serves as a risk factor

Urinalysis is mandatory across all age groups—UTI is the most common serious bacterial infection in this population 1.

Shared Decision-Making Framework

For infants 22-60 days meeting low-risk criteria, discuss with parents 1:

• Risk of invasive bacterial infection (<1% if low-risk criteria met vs >5% if inflammatory markers abnormal)
• Benefits of avoiding lumbar puncture (pain, complications, potential for traumatic tap)
• Risks of missing bacterial meningitis (rare but devastating)
• Need for close follow-up and potential for future LP if clinical deterioration
• Document these discussions thoroughly 1

Common Pitfalls to Avoid

• Don't use the old Rochester/Philadelphia/Boston criteria—they've been replaced by this evidence-based guideline 2
• Don't skip urinalysis—even if other tests are normal, UTI can occur in isolation
• Don't use oral antibiotics in infants <29 days old—they require parenteral therapy 1
• Don't discharge without ensuring reliable follow-up—clinical deterioration can occur rapidly 4
• Don't forget to adjust antibiotics based on local antibiogram patterns 1

Antimicrobial Resistance Considerations

The guideline acknowledges the tension between treating potential serious bacterial infections and contributing to antimicrobial resistance 1. This is why risk stratification using inflammatory markers is crucial—it allows clinicians to safely avoid antibiotics in truly low-risk infants while ensuring high-risk infants receive prompt treatment.

Special Populations Requiring Different Approaches

• Infants <8 days old: Not covered by this guideline; require evaluation for early-onset sepsis with different pathogens (Group B Streptococcus, E. coli) 2
• Post-immunization fever: Consider timing of recent vaccines in risk assessment 4
• Suspected herpes simplex virus: Requires acyclovir and different evaluation pathway 5